Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.

Holger N. Lode,Dominique Valteau-Couanet,Juliet Gray,Roberto Luksch,Aleksandra Wieczorek,Victoria Castel,Shifra Ash,Genevieve Laureys,Vassilios Papadakis,Cormac Owens,Alberto Garaventa,Carla Manzitti,Nikolai Siebert,Sascha Troschke-Meurer,Evgenia Glogova,Ulrike Poetschger,Ruth Lydia Ladenstein

Journal of Clinical Oncology（2019）

引用 13|浏览122

暂无评分

摘要

10014Background: We determined the role of scIL-2 combined with long term infusion (LTI) of DB in patients (pts) with high-risk relapsed/refractory neuroblastoma. Methods: 160 pts were enrolled int...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要